Ken Pittman

836 total citations
23 papers, 292 citations indexed

About

Ken Pittman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ken Pittman has authored 23 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in Ken Pittman's work include Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Diagnosis and Treatment (3 papers). Ken Pittman is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Diagnosis and Treatment (3 papers). Ken Pittman collaborates with scholars based in Australia, United Kingdom and Barbados. Ken Pittman's co-authors include Timothy Price, Janice Fletcher, Louise Nott, Peter J. Selby, Colin Luke, Christos S. Karapetis, Bogda Koczwara, Amanda Townsend, David Roder and Dusan Kotasek and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Ken Pittman

23 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ken Pittman Australia 10 139 55 51 48 38 23 292
Yumiko Inui Japan 8 86 0.6× 68 1.2× 66 1.3× 12 0.3× 35 0.9× 30 300
Antonieta Solar Chile 11 136 1.0× 76 1.4× 93 1.8× 83 1.7× 40 1.1× 31 420
Agathi Pafiti Greece 13 77 0.6× 51 0.9× 50 1.0× 92 1.9× 51 1.3× 33 448
A Chlumská Czechia 12 70 0.5× 53 1.0× 99 1.9× 58 1.2× 90 2.4× 65 428
S Costantini Italy 9 121 0.9× 144 2.6× 59 1.2× 31 0.6× 49 1.3× 19 379
Mustafa Adlı Türkiye 13 95 0.7× 29 0.5× 76 1.5× 56 1.2× 21 0.6× 31 459
Kwang Sun Suh South Korea 11 56 0.4× 48 0.9× 83 1.6× 96 2.0× 60 1.6× 27 345
Vahit Yükselen Türkiye 11 59 0.4× 25 0.5× 55 1.1× 41 0.9× 55 1.4× 28 439
Agnieszka Szymczyk Poland 9 115 0.8× 62 1.1× 26 0.5× 21 0.4× 83 2.2× 40 368
Halil Ateş Türkiye 12 82 0.6× 50 0.9× 41 0.8× 30 0.6× 114 3.0× 31 368

Countries citing papers authored by Ken Pittman

Since Specialization
Citations

This map shows the geographic impact of Ken Pittman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Pittman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Pittman more than expected).

Fields of papers citing papers by Ken Pittman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Pittman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Pittman. The network helps show where Ken Pittman may publish in the future.

Co-authorship network of co-authors of Ken Pittman

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Pittman. A scholar is included among the top collaborators of Ken Pittman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Pittman. Ken Pittman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Singhal, Nimit, Anna Rachelle Mislang, Rajiv Kumar, et al.. (2017). Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer. Asia-Pacific Journal of Clinical Oncology. 14(1). 91–100. 9 indexed citations
2.
Pittman, Ken, et al.. (2015). Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?. BMJ Case Reports. 2015. bcr2014207750–bcr2014207750. 6 indexed citations
3.
Wilcken, Nicholas, Nicholas Zdenkowski, Michelle White, et al.. (2014). Systemic treatment of HER2‐positive metastatic breast cancer: A systematic review. Asia-Pacific Journal of Clinical Oncology. 10(S4). 1–14. 17 indexed citations
4.
Boer, Richard de, Jane Beith, Jacquie Chirgwin, et al.. (2014). Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives. Asia-Pacific Journal of Clinical Oncology. 10(S4). 15–25. 1 indexed citations
5.
Khattak, Muhammad A., et al.. (2011). Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide. BMJ Case Reports. 2011. bcr0420102917–bcr0420102917. 3 indexed citations
6.
Luke, Colin, et al.. (2011). Epidemiology of cancers of the kidney in an Australian population.. PubMed. 12(11). 2893–9. 14 indexed citations
7.
Townsend, Amanda, et al.. (2010). Metastatic Carcinoid Tumor. Journal of Clinical Gastroenterology. 44(3). 195–199. 21 indexed citations
8.
9.
Luke, Colin, Bogda Koczwara, Christos S. Karapetis, et al.. (2008). Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Australian and New Zealand Journal of Public Health. 32(4). 383–389. 31 indexed citations
10.
Townsend, Amanda, et al.. (2008). Fluorouracil-induced Hepatic Artery Spasm Preventing Yttrium-90 Microsphere Administration. Clinical Nuclear Medicine. 33(8). 528–530. 2 indexed citations
11.
Nott, Louise, et al.. (2008). Hyperammonaemic encephalopathy associated with rituximab‐containing chemotherapy. Internal Medicine Journal. 38(10). 800–803. 9 indexed citations
12.
Nott, Louise, et al.. (2007). Successfully improving access and accrual to oncology clinical trials. Cancer. 109(8). 1451–1453. 3 indexed citations
13.
Nott, Louise, et al.. (2007). Hyperammonemia encephalopathy: An important cause of neurological deterioration following chemotherapy. Leukemia & lymphoma. 48(9). 1702–1711. 83 indexed citations
14.
Luke, Colin, Grantley Gill, Stephen N. Birrell, et al.. (2006). Treatment and survival from breast cancer: the experience of patients at South Australian teaching hospitals between 1977 and 2003. Journal of Evaluation in Clinical Practice. 13(2). 212–220. 6 indexed citations
15.
Pittman, Ken, Ian Olver, Bogda Koczwara, et al.. (2006). Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. British Journal of Cancer. 95(10). 1309–1313. 32 indexed citations
16.
Price, Timothy, Ken Pittman, Sung Hoon Sim, et al.. (2004). Survival and treatment trends for advanced colorectal cancer (CRC) treated in a University Hospital, 1992–2001. Journal of Clinical Oncology. 22(14_suppl). 3707–3707. 1 indexed citations
17.
Karapetis, Christos S., W. K. Patterson, Ken Pittman, Dusan Kotasek, & Robert Sage. (1999). Treatment of metastatic breast cancer with continuous infusional 5 fluorouracil. Australian and New Zealand Journal of Medicine. 29(4). 517–522. 5 indexed citations
18.
Pittman, Ken & Peter J. Selby. (1994). The management of renal cell carcinoma. Critical Reviews in Oncology/Hematology. 16(3). 181–200. 19 indexed citations
19.
Pittman, Ken. (1992). A laboratory for the visualization of virtual environments. Landscape and Urban Planning. 21(4). 327–331. 7 indexed citations
20.
Pittman, Ken, Charles L. M. Olweny, J. B. North, & P. C. Blumbergs. (1991). Primary Central Nervous System Lymphoma. Oncology. 48(3). 184–187. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yumiko Inui Breakdown of academic impact, for papers by Antonieta Solar Breakdown of academic impact, for papers by Agathi Pafiti Breakdown of academic impact, for papers by A Chlumská Breakdown of academic impact, for papers by S Costantini Breakdown of academic impact, for papers by Mustafa Adlı Breakdown of academic impact, for papers by Kwang Sun Suh Breakdown of academic impact, for papers by Vahit Yükselen Breakdown of academic impact, for papers by Agnieszka Szymczyk Breakdown of academic impact, for papers by Halil Ateş
Rankless by CCL
2026